0000000000525888

AUTHOR

Carlos Capalbo

showing 1 related works from this author

HER2-positive male breast cancer: an update.

2010

Laura Ottini1, Carlo Capalbo2, Piera Rizzolo1, Valentina Silvestri1, Giuseppe Bronte3, Sergio Rizzo3, Antonio Russo31Department of Experimental Medicine, “Sapienza” University of Rome, Rome, Italy; 2Medical Oncology, IDI-IRCCS, Rome, Italy; 3Department of Surgical and Oncological Sciences, Section of Medical Oncology, University of Palermo, Palermo, ItalyAbstract: Although rare, male breast cancer (MBC) remains a substantial cause for morbidity and mortality in men. Based on age frequency distribution, age-specific incidence rate pattern, and prognostic factor profiles, MBC is considered similar to postmenopausal breast cancer (BC). Compared with female BC (FBC), MBC cas…

Oncologymedicine.medical_specialtymedicine.medical_treatmentEstrogen receptorReviewPharmacologyLapatinibTarget therapyBreast cancerTrastuzumabInternal medicinemedicineEpidermal growth factor receptorskin and connective tissue diseasesneoplasmsNeoadjuvant therapybiologybusiness.industryLapatinibTargets and Therapy [Breast Cancer]Trastuzumabmedicine.diseaseRadiation therapyOncologyMale breast cancerbiology.proteinbusinessmedicine.drug
researchProduct